Lawrence Parish, MD
Dermatology · Philadelphia, PANPI 1548259815
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $4,258 of the $5,777 with a category attached, or 73.7%. 6 manufacturers reported payments, led by UCB Biosciences Inc. at 36.0% of the total. Reporting peaked in 2020 at $2,095 and has fallen 92.7% since, to $153 in 2025.
Across 64 payments — averaging $90.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB Biosciences Inc.$2K
- Pfizer$2K
- Bristol Myers Squibb$1K
- AbbVie$314
- Johnson & Johnson$80
- VYNE Pharmaceuticals Inc.$13
Across 639 payments — averaging $4707.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$939K
- Eli Lilly$485K
- Janssen Research & Development, LLC$416K
- UCB SA$377K
- GSK$184K
- AbbVie$138K
- plus $469K from 10 others
What the payments were for
- Travel & lodging$4,25874%
- Food & beverage$1,43925%
- Education$801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB Biosciences Inc. | 18 | $2,082 |
| Pfizer | 5 | $1,948 |
| Bristol Myers Squibb | 6 | $1,340 |
| AbbVie | 33 | $314 |
| Johnson & Johnson | 1 | $80 |
| VYNE Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$1,263
- Bimekizumab$802
How this compares
$5,777 in reported general payments places this provider in the 70th percentile of 626 dermatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 12 | $251,864 |
| Humira(Cf) PenAdalimumab | 17 | $111,657 |
| Clobetasol Propionate | 77 | $5,329 |
| Desonide | 15 | $2,047 |
| Hydrocortisone | 46 | $1,038 |
| Triamcinolone Acetonide | 75 | $692 |
| Fluticasone Propionate | 38 | $569 |
| Pentoxifylline | 13 | $560 |
| Ketoconazole | 29 | $442 |
| Terbinafine Hcl | 22 | $188 |
| Minoxidil | 14 | $160 |
| Hydroxyzine Hcl | 12 | $115 |
| Prednisone | 17 | $72 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Philadelphia
- Stephen HessPhiladelphia$1.7M
- Joel GelfandPhiladelphia$649K
- Victoria WerthPhiladelphia$547K
- Nicholas MollanazarPhiladelphia$369K
- Harold FarberPhiladelphia$284K
- Jules LipoffPhiladelphia$259K
- Susan TaylorPhiladelphia$207K
- Joy WanPhiladelphia$176K
- Harold MilsteinPhiladelphia$120K
- David MargolisPhiladelphia$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.